Cyrus Mozayeni
Directeur Général chez Novartis Optogenetics Research, Inc.
Profil
Cyrus D.
Mozayeni was the founder of Oncorus, Inc. (founded in 2015) where he held the position of President & Chief Business Officer from 2015 to 2018.
Dr. Mozayeni is also the founder of Vedere Bio II, Inc. Dr. Mozayeni's current job is President, CEO, Treasurer & Director at Novartis Optogenetics Research, Inc. and Chief Executive Officer at Pheon Therapeutics Ltd.
(starting in 2023).
Dr. Mozayeni's former jobs include Director-Strategic Business Development at PPD Dermatology LLC, Principal at Avera Pharmaceuticals, Inc., VP-Business Development & Alliance Management at bluebird bio, Inc., and Member at Northwestern University.
Dr. Mozayeni's education includes an undergraduate degree from Brown University, an MBA from Kellogg School of Management, and a doctorate from The University of Virginia School of Medicine.
Postes actifs de Cyrus Mozayeni
| Sociétés | Poste | Début |
|---|---|---|
Novartis Optogenetics Research, Inc.
 Novartis Optogenetics Research, Inc. BiotechnologyHealth Technology Vedere Bio, Inc. develops cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss. The company was founded in June 2019 and is headquartered in Cambridge, MA. | Directeur Général | - |
Vedere Bio II, Inc.
 Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Directeur Général | - |
Pheon Therapeutics Ltd.
 Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Directeur Général | 25/07/2023 |
Anciens postes connus de Cyrus Mozayeni
| Sociétés | Poste | Fin |
|---|---|---|
| ONCORUS, INC. | Fondateur | 01/08/2018 |
PPD Dermatology LLC
 PPD Dermatology LLC Pharmaceuticals: MajorHealth Technology PPD Dermatology LLC develops novel pharmaceutical products and proprietary medical therapies for the dermatology market. The company provides therapies for skin diseases. It was founded in 2006 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses | Corporate Officer/Principal | - |
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | - |
Avera Pharmaceuticals, Inc.
 Avera Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Avera Pharmaceuticals, Inc. develops drugs and therapies. The company's pharmaceutical compounds are used to identify opportunities for therapeutic advances in the treatment of neurological and psychiatric disorders. Avera Pharmaceuticals was founded in 2002 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
Formation de Cyrus Mozayeni
| Brown University | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
| The University of Virginia School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| ONCORUS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Avera Pharmaceuticals, Inc.
Avera Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Avera Pharmaceuticals, Inc. develops drugs and therapies. The company's pharmaceutical compounds are used to identify opportunities for therapeutic advances in the treatment of neurological and psychiatric disorders. Avera Pharmaceuticals was founded in 2002 and is headquartered in San Diego, CA. | Health Services |
PPD Dermatology LLC
PPD Dermatology LLC Pharmaceuticals: MajorHealth Technology PPD Dermatology LLC develops novel pharmaceutical products and proprietary medical therapies for the dermatology market. The company provides therapies for skin diseases. It was founded in 2006 and is headquartered in Waltham, MA. | Health Technology |
Novartis Optogenetics Research, Inc.
Novartis Optogenetics Research, Inc. BiotechnologyHealth Technology Vedere Bio, Inc. develops cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss. The company was founded in June 2019 and is headquartered in Cambridge, MA. | Health Technology |
Vedere Bio II, Inc.
Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Commercial Services |
Pheon Therapeutics Ltd.
Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Health Technology |
